Three months after hearing loss-focused company Akouos secured $105 million in a Series B financing round, the Boston-based company is eying an initial public offering valued at about $100 million.
https://www.pharmalive.com/wp-content/uploads/2020/06/Akouos-Eyes-100-Million-IPO-to-Support-Gene-Therapy-Programs-for-Hearing-Loss-BioSpace-6-8-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-06-08 11:16:262020-06-15 18:38:31Akouos Eyes IPO to Support Gene Therapy Programs for Hearing Loss